Order Article Reprints

Scotto R, Buonomo AR, Iuliano A, Foggia M, Sardanelli A, Villari R, Pinchera B, Gentile I, Federico II COVID-Team. Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study. Vaccines. 2023; 11(2):200. https://doi.org/10.3390/vaccines11020200

Scotto, Riccardo, Antonio Riccardo Buonomo, Antonio Iuliano, Maria Foggia, Alessia Sardanelli, Riccardo Villari, Biagio Pinchera, Ivan Gentile, and Federico II COVID-Team. 2023. "Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study" Vaccines 11, no. 2: 200. https://doi.org/10.3390/vaccines11020200

Scotto, R., Buonomo, A. R., Iuliano, A., Foggia, M., Sardanelli, A., Villari, R., Pinchera, B., Gentile, I., & Federico II COVID-Team. (2023). Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study. Vaccines, 11(2), 200. https://doi.org/10.3390/vaccines11020200